<?xml version="1.0" encoding="UTF-8"?>
<xml>
 <records>
  <record>
   <ref-type name="Journal Article">17</ref-type>
   <contributors>
    <authors>
     <author>Spasov, A.A.</author>
     <author>Khaliullin, F.A.</author>
     <author>Babkov, D.A.</author>
     <author>Timirkhanova, G.A.</author>
     <author>Kuznetsova, V.A.</author>
     <author>Naumenko, L.V.</author>
     <author>Muleeva, D.R.</author>
     <author>Maika, O.Yu.</author>
     <author>Prokhorova, T.Yu.</author>
     <author>Sturova, E.A.</author>
    </authors>
   </contributors>
   <titles>
    <title></title>
   </titles>
   <dates>
    <year>2017</year>
    <pub-dates>
     <date>2018-03-07</date>
    </pub-dates>
   </dates>
   <doi>10.1007/s11094-017-1649-5</doi>
   <abstract>Thiazolo[2, 3-f]purine derivatives and their analogs – dihydrothiazolo[2, 3-f]purine, 7-(thietan-3-yl)purine,&#13;
and 8-(2-hydroxypropylthio)purine derivatives – were synthesized. The compounds synthesized here had no&#13;
effects on protein glycation reactions using glucose; they gave weak inhibition of glycogen phosphorylase;&#13;
they had no hemorheological activity. Substances with hypotensive activity greater than that of Dibazol were&#13;
found. A number of substances had hypoglycemic effects greater than those of chlorpropamide and Adebit.&#13;
Two compounds inhibited dipeptidylpeptidase-4, but were less active than reference agent vildagliptin.</abstract>
   <urls>
    <web-urls>
     <url>https://repo.bashgmu.ru/publication/1126</url>
    </web-urls>
    <pdf-urls>
     <url>https://repo.bashgmu.ru/files/1283</url>
    </pdf-urls>
   </urls>
  </record>
 </records>
</xml>
